tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Insmed price target raised to $180 from $110 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Insmed (INSM) to $180 from $110 and keeps an Outperform rating on the shares. The firm sees Insmed entering its “next big growth phase” with Brinsupri launching in NCFB, the analyst tells investors. Phase 3 CRSsNP data due by year-end 2025 could yield “yet another” roughly $3B opportunity, the analyst contends.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1